$-0.07 EPS Expected for Oasmia Pharmaceutical AB (OASM)

August 26, 2017 – By Dolores Ford

 $ 0.07 EPS Expected for Oasmia Pharmaceutical AB (OASM)

Analysts await Oasmia Pharmaceutical AB (STO:OASM) to report earnings on September, 1. After $-0.12 actual EPS reported by Oasmia Pharmaceutical AB for the previous quarter, Wall Street now forecasts -41.67 % EPS growth. The stock increased 1.06% or $0.03 on August 25, reaching $2.85. About 490,970 shares traded or 9.51% up from the average. Oasmia Pharmaceutical AB (STO:OASM) has declined 35.00% since August 26, 2016 and is downtrending. It has underperformed by 51.70% the S&P500.

Oasmia Pharmaceutical AB is a Sweden pharmaceutical firm engaged in the field of human and veterinary oncology. The company has market cap of $503.13 million. The Company’s activities are divided into two divisions: Human Health and Animal Health. It currently has negative earnings. The Human Health segment specializes in ovarian and breast cancer.

More notable recent Oasmia Pharmaceutical AB (STO:OASM) news were published by: Globenewswire.com which released: “Issuance of warrants in Oasmia Pharmaceutical AB (publ)” on June 21, 2017, also Globenewswire.com with their article: “Oasmia Pharmaceutical AB (publ) publishes prospectus by reason of the Rights Issue” published on June 19, 2017, Globenewswire.com published: “Oasmia Pharmaceutical to spin-off veterinary assets” on May 10, 2017. More interesting news about Oasmia Pharmaceutical AB (STO:OASM) were released by: Globenewswire.com and their article: “NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB” published on August 25, 2017 as well as Globenewswire.com‘s news article titled: “Oasmia Pharmaceutical Invites Shareholders to Capital Markets Day in Stockolm …” with publication date: May 23, 2017.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter:

Recent Posts